Interactive Clinical Discussion on XPOVIO

Written by patrippon on April 28, 2020.

04/28/20

6:00 pm - 8:00 pm

XPOVIO® (selinexor) The first and only FDA-approved oral selective nuclear export inhibitor in relapsed refractory multiple myeloma (RRMM)

Virtual Event through Adobe Connect

Presented by:
Joseph Mikhael, MD
Translational Genomics Research Institute (City of Hope)

To RSVP, please email KaryopharmRSVP@PW.Veeva.com or call 866-914-9069

Please Note: You will receive log-in/dial-in details once you are successfully registered

KAR0000856 Please reference this number during registration.